Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Public ClinicalTrials.gov record NCT01047683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
Study identification
- NCT ID
- NCT01047683
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Oct 2010 (Actual)
- Completion
- Jul 2011 (Actual)
- Last update posted
- Apr 25, 2022
2009 – 2011
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Amarin Investigational Site | Sacramento | California | 95823 | — |
| Amarin Investigational Site | Golden | Colorado | 80401 | — |
| Amarin Investigational Site | Miami | Florida | 33169 | — |
| Amarin Investigational Site | Miami | Florida | 33183 | — |
| Amarin Investigational Site | Ocala | Florida | 34471 | — |
| Amarin Investigational Site | Addison | Illinois | 27106 | — |
| Amarin Investigational Site | Chicago | Illinois | 60611 | — |
| Amarin Investigational Site | Louisville | Kentucky | 40213 | — |
| Amarin Investigational Site | Butte | Montana | 59701 | — |
| Amarin Investigational Site | Raleigh | North Carolina | 27527 | — |
| Amarin Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Amarin Investigational Site | Cincinnati | Ohio | 45212 | — |
| Amarin Investigational Site | Cincinnati | Ohio | 45219 | — |
| Amarin Investigational Site | Lyndhurst | Ohio | 44124 | — |
| Amarin Investigational Site | Tulsa | Oklahoma | 74136 | — |
| Amarin Investigational Site | Corpus Christi | Texas | 78404 | — |
| Amarin Investigational Site | Houston | Texas | 77030 | — |
| Amarin Investigational Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01047683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 25, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01047683 live on ClinicalTrials.gov.